Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

Author:

Nolan Beatrice1ORCID,Mahlangu Johnny2ORCID,Pabinger Ingrid3,Young Guy45ORCID,Konkle Barbara A.6ORCID,Barnes Chris7,Nogami Keiji8ORCID,Santagostino Elena9,Pasi K. John10ORCID,Khoo Liane11,Winding Bent12,Yuan Huixing13,Fruebis Joachim14,Rudin Dan14,Oldenburg Johannes15ORCID

Affiliation:

1. Children's Health Ireland at Crumlin Dublin Ireland

2. Haemophilia Comprehensive Care Centre Faculty of Health Sciences Charlotte Maxeke Johannesburg Academic Hospital and NHLS University of Witwatersrand Johannesburg South Africa

3. Medizinische Universität Wien Vienna Austria

4. Children’s Hospital Los Angeles Los Angeles CA USA

5. University of Southern California Keck School of Medicine Los Angeles CA USA

6. Bloodworks Northwest Seattle WA USA

7. The Royal Children’s Hospital Parkville Vic. Australia

8. Nara Medical University Kashiwara Japan

9. Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico Milan Italy

10. Royal London Haemophilia Centre Barts and The London School of Medicine and Dentistry London UK

11. Royal Prince Alfred Hospital Camperdown NSW Australia

12. Sobi Stockholm Sweden

13. Sanofi Cambridge MA USA

14. Bioverativ, a Sanofi company Waltham MA USA

15. Institute of Experimental Haematology and Transfusion Medicine University Clinic Bonn Bonn Germany

Funder

Sanofi

Swedish Orphan Biovitrum

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Reference29 articles.

1. National Hemophilia Foundation.MASAC document 241: MASAC recommendations concerning Prophylaxis.https://www.hemophilia.org/Researchers‐Healthcare‐Providers/Medical‐and‐Scientific‐Advisory‐Council‐MASAC/MASAC‐Recommendations/MASAC‐Recommendation‐Concerning‐Prophylaxis. Accessed October 25 2018.

2. Individualizing prophylaxis in hemophilia: a review

3. Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?

4. Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials

5. Hemophilia A in the third millennium

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3